Lavipharm

Lavipharm Net Debt

The Net Debt of Lavipharm (LAVI.AT) as of Nov 2, 2026 is 22.26 M EUR. In the previous year, Net Debt was 28.23 M EUR — a change of -21.14% (lower).

Net Debt

22.26 MEUR

YoY

-21.14%

Last updated:

Net Debt of Lavipharm is 2025 22.26 M EUR. Net Debt of Lavipharm was 2024 28.23 M EUR. It decreases by -21.14% lower compared to the previous year.

The Lavipharm Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
38.70 M EUR
Jan 1, 2019
38.98 M EUR
Jan 1, 2020
34.33 M EUR
Jan 1, 2021
35.69 M EUR
Jan 1, 2022
18.82 M EUR
Jan 1, 2023
23.93 M EUR
Jan 1, 2024
28.23 M EUR
Jan 1, 2025
22.26 M EUR
The Lavipharm Net Debt history
YEARNet DebtYoY
22.26 MEUR-21.14%
28.23 MEUR+17.93%
23.93 MEUR+27.15%
18.82 MEUR-47.26%
35.69 MEUR+3.97%
34.33 MEUR-11.93%
38.98 MEUR+0.72%
38.70 MEUR-1.10%
39.13 MEUR-49.43%
77.39 MEUR-5.46%
81.86 MEUR+32.04%
61.99 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Net Debt of Lavipharm is 22.26 M EUR in 2025.

Net Debt of Lavipharm changed from 28.23 M EUR to 22.26 M EUR, representing a -21.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Lavipharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lavipharm

All Key Metrics — Lavipharm